Evidence map›Paper›PMID 28106820›Full record

ReviewSensors (Basel, Switzerland)2017

Current and Emerging Technology for Continuous Glucose Monitoring.

Cheng Chen, Xue-Ling Zhao, Zhan-Hong Li, Zhi-Gang Zhu, Shao-Hong Qian, Andrew J Flewitt

Open access · goldAbstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 281 citations in OpenAlex.

  1. Tissue Response to Subcutaneous Infusion Catheter.Journal of diabetes science and technology · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. [Research progress on automated insulin delivery system in the field of diabetes management].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Predicting Blood Glucose Levels with Organic Neuromorphic Micro-Networks.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Cheng ChenSchool of Environmental and Materials Engineering, College of Engineering, Shanghai Polytechnic University, Shanghai 201209, China. chencheng@sspu.edu.cn.
Xue-Ling ZhaoSchool of Environmental and Materials Engineering, College of Engineering, Shanghai Polytechnic University, Shanghai 201209, China. xlzhao@sspu.edu.cn.
Zhan-Hong LiSchool of Environmental and Materials Engineering, College of Engineering, Shanghai Polytechnic University, Shanghai 201209, China. zhli@sspu.edu.cn.
Zhi-Gang ZhuSchool of Environmental and Materials Engineering, College of Engineering, Shanghai Polytechnic University, Shanghai 201209, China. zgzhu@sspu.edu.cn.
Shao-Hong QianDepartment of Ophthalmology, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai 200231, China. qsh2304@163.com.
Andrew J FlewittElectrical Engineering Division, Department of Engineering, University of Cambridge, J J Thomson Avenue, Cambridge CB3 0FA, UK. ajf@eng.cam.ac.uk.
Shanghai Polytechnic University · CNEye & ENT Hospital of Fudan University · CNUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes has become a leading cause of death worldwide. Although there is no cure for diabetes, blood glucose monitoring combined with appropriate medication can enhance treatment efficiency, alleviate the symptoms, as well as diminish the complications. For point-of-care purposes, continuous glucose monitoring (CGM) devices are considered to be the best candidates for diabetes therapy. This review focuses on current growth areas of CGM technologies, specifically focusing on subcutaneous implantable electrochemical glucose sensors. The superiority of CGM systems is introduced firstly, and then the strategies for fabrication of minimally-invasive and non-invasive CGM biosensors are discussed, respectively. Finally, we briefly outline the current status and future perspective for CGM systems.

Indexed as

Blood GlucoseDiabetes MellitusHumansMonitoring, PhysiologicPoint-of-Care SystemsBlood Glucosecontinuous glucose monitoringglucose biosensorimplanted devicesmini-invasivenon-invasive

Identifiers

PMID28106820
PMCPMC5298755
OpenAlexW2577350032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.